# Toclizumam Versus Dexamethasone in Severe Covid-19 Cases

> **NCT04519385** · NA · COMPLETED · sponsor: **South Valley University** · enrollment: 69 (actual)

## Conditions studied

- Pneumonia, Viral

## Interventions

- **DRUG:** Tocilizumab
- **DRUG:** Dexamethasone

## Key facts

- **NCT ID:** NCT04519385
- **Lead sponsor:** South Valley University
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-03-01
- **Primary completion:** 2020-07-01
- **Final completion:** 2020-08-05
- **Target enrollment:** 69 (ACTUAL)
- **Last updated:** 2020-08-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04519385

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04519385, "Toclizumam Versus Dexamethasone in Severe Covid-19 Cases". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT04519385. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*